Every one of those 1 sits in a single category, pharma. Aparna Thakur is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 3 original sources on average, compared with 2.4 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Jnana Therapeutics
Every one of those 1 sits in a single category, pharma. Aparna Thakur is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 3 original sources on average, compared with 2.4 for the broader beat in this window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 1 Biotech story that mention Jnana Therapeutics, all published on February 19, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Jnana Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
The global Phenylketonuria (PKU) market is projected to expand significantly through 2034, fueled by a robust pipeline of next-generation therapies and enhanced diagnostic screening. With the United States leading in diagnosed prevalence, major players like BioMarin, PTC Therapeutics, and Jnana are racing to address the metabolic limitations of current standard-of-care treatments.